PIRAMAL DISCOVERY SOLUTIONS



Similar documents
Presented at: Jefferies 2015 Global Healthcare Conference

Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences

We use Reaxys intensively for hit identification, hit-to-lead and lead optimization.

C 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to

An Industry White Paper

Brand Quality with Asian Advantages

Highly Potent APIs The right platform, people and procedures for successful development and manufacturing

An integrated global healthcare company

Call 2014: High throughput screening of therapeutic molecules and rare diseases

DMPK: Experimentation & Data

Exploiting the Pathogen box

NEW CHEMICAL ENTITIES

Valentina Gualato, Ph.D. Process Development Scientist

Corporate Presentation November, 2013

Working with ICH Quality Guidelines - the Canadian Perspective

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5

BIOTECHNOLOGY OPERATIONS

Lead optimization services

Data Visualization in Cheminformatics. Simon Xi Computational Sciences CoE Pfizer Cambridge

Bachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements

Academic Drug Discovery in the Center for Integrative Chemical Biology and Drug Discovery

Eudendron: an Innovative Biotech Start-up

UK- India Science Bridge: BioPharm 2020

exactly. The need for efficiency in developing effective new therapeutics has never been greater.

Drug Discovery in China

Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH

Accelerating Lead Generation: Emerging Technologies and Strategies

BIOTECHNOLOGY. about biotechnology

OPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY

MSC IN MEDICINAL CHEMISTRY

Introduction to Enteris BioPharma

Pharmaceutical Sciences

SERVICES FOR. Devices and Combination Products

Bioservices. Your lab just got bigger

The agency perspective: What we do and how we do it

Catalent Biologics & Clinical Supplies The SMART Solution

Diabetes and Drug Development

Selvita Integrated drug discovery collaborations

The Clinical Trials Process an educated patient s guide

Managing Joint Venture Arrangements Between Two Biotech Companies: A Case Report. Dr. Jan Mous Midatech / PharMida May 21 st 2014

Medicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia

Non-clinical development of biologics

Automating Cell Biology Annual general meeting, September 7, Phase Holographic Imaging

High-Throughput Screening at The University of Chicago Cellular Screening Center. Sam Bettis Technical Director

CTC Technology Readiness Levels

THE BIOTECH & PHARMACEUTICAL INDUSTRY

TERM SHEET EXAMPLE. 1 P age

Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013

Life Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com

STRUCTURE-GUIDED, FRAGMENT-BASED LEAD GENERATION FOR ONCOLOGY TARGETS

Technology and Expertise Add Operational Value to Medical Device Trials

Ph.D. Science & Engineering Positions. Wilmington, DE. Analytical Sciences Wilmington, DE. Sciences Wilmington, DE.

Dr.ssa Maria Luisa Nolli CEO

Normand Laberge Vice-President Regulatory & Scientific Affairs Rx&D. Globalization of Clinical Research: Trends & Implications for Canada

Providing Trusted and Innovative Solutions t o the Life Science Communities

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010

Product Life Cycle Management in Life Sciences Industry

Pharmaceutical Quality Management System: Current Concept

Cell Discovery 360: Explore more possibilities.

19 October Company Announcement Office Bendigo Stock Exchange PO Box 191 Flinders Lane, Melbourne Vic By ;

Engineering for the new pharma reality

Your partner in immunology

Orphan Pharma: pathfinders for an increasingly specialised industry

Delcin Consulting Group

Crossing the drug development divide

Overview of Drug Development: the Regulatory Process

Multitude of opportunities for Finnish pharmaceutical industry in India

Open PHACTS Workshop, February The Lilly Perspective: Challenges We Face & Tools We Need

Making the most of academic drug target discoveries

MEDICAL DEVICE & DIAGNOSTICS

Biological importance of metabolites. Safety and efficacy aspects

Company Presentation June 2011 Biotest AG 0

AAGPs TM Anti-Aging Glyco Peptides. Enhancing Cell, Tissue and Organ Integrity Molecular and biological attributes of lead AAGP molecule

GRADUATE CERTIFICATE IN GOOD MANUFACTURING PRACTICE (GMP) Plan your career for tomorrow and you will be ahead of your competitors

INSERT COMPANY LOGO HERE BEST PRACTICES RESEARCH

4.1 Objectives of Clinical Trial Assessment

GenScript USA Inc. Open Position List

Curriculum Vitae. Prof. Dr. Bernhard Kutscher, Ph.D. Personal Details. Education

A Peak at PK An Introduction to Pharmacokinetics

PEOPLE > SCIENCE > SOLUTIONS

PHARMACEUTICAL QUALITY SYSTEM Q10

Course Curriculum for Master Degree in Clinical Pharmacy

REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023

Sparta Systems. Proven Enterprise Quality Management Solutions

Annual Report on Form 20-F

De novo design in the cloud from mining big data to clinical candidate

KMS-Specialist & Customized Biosimilar Service

novo nordisk Partnering for innovation IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES Protein Technologies Diabetes Protein Delivery Devices

Open Innovation: An Imperative for the Pharmaceutical Industry. Berkeley Innovation Forum

Florida Translational Research Program (FTRP)

Clinical Trial Trends Outline Complexity for Supply Chain. Scott Ohanesian, VP Commercial Operations APAC

BioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma

Product Lifecycle Management in the Aerospace Arena

Introduction to pharmaceutical technology

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS

Dear Business Development or Corporate Alliance Director/Manager,

Kinexus has an in-house inventory of lysates prepared from 16 human cancer cell lines that have been selected to represent a diversity of tissues,

QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES

Transcription:

PIRAMAL DISCOVERY SOLUTIONS Pharma Solutions products and services

Delivering Globally Integrated Solutions across the drug lifecycle We are the Contract Development & Manufacturing arm of Piramal Healthcare, a part of Piramal Enterprises Ltd. Our capability as an integrated solutions provider enables us to serve Innovator and Generic companies worldwide. Our customers can avail a comprehensive range of services across all phases of the drug lifecycle which includes Drug Discovery & Development, Manufacturing and Packaging of Clinical Trial Supplies, Delivering Commercial Volumes of APIs as well as Finished Dosage products. To provide flexibility and scalability of operations, we have invested in a network of contract development and manufacturing facilities located in North America, Europe and Asia. Our roots We are an integral part of Piramal Enterprises Ltd., a leading business group in India with multiple business interests. As a Group, we are committed to achieving excellence and leadership by practicing our core values of knowledge, action and care. We adhere to innovative, value-driven practices in our diverse business initiatives, ranging from healthcare and glass manufacturing to real-estate. Our beginning in the Healthcare business goes back to the year 1988 when we acquired Nicholas Laboratories. Since then we have grown into a leading pharmaceutical company in India and a dominant player on a global level. With the changing dynamics of the pharmaceutical industry worldwide, innovation and cost have emerged as key challenges for pharmaceutical companies worldwide. We enable our customers to address these challenges by offering cost effective and reliable delivery solutions across the product lifecycle. Canada Toronto India Ahmedabad Ennore Pithampur Digwal Mumbai U.S.A Boston United Kingdom Grangemouth Morpeth Cambridge China Shanghai(Sourcing Office)

The advantage we carry Our customers enjoy the benefits of our global network of assets spread across Europe, North America and Asia. Our network enables us to deliver benefits by strategically placing projects to take advantage of low costs, local supply chains and specific customer/ market requirements. Piramal Enterprises Ltd., currently valued at more than 1 billion USD, is amongst the largest business conglomerates in India. We embrace a rich legacy of over 20 years in the business of healthcare. Our R&D team is led by scientists with experience of working with pharma companies across the globe and hold expertise across various chemistries and range of formulation types. Global Network Integrated Solutions Financial Stability Consistent Track Record People & Science Hallmark of Quality & Safety With capabilities across drug discovery, development, scaleup and manufacturing of APIs as well as Formulations, we are well positioned to address customers needs across the entire drug lifecycle. Our specialization in Antibody Drug Conjugation, Clinical Trial Supplies, Packaging and Biocatalysis enables us to provide differentiated services to our customers. We are a pioneer in the Contract Development and Manufacturing Services market and have an experience of over two decades. We have advanced manufacturing facilities approved by leading regulatory agencies including the US-FDA and MHRA. We are a trusted supplier to more than 100 pharma companies across the US, Europe and Japan including all major Big Pharma and large Generic companies. We believe that the best can be delivered if only there is an internal focus on quality. Stringent quality and safety norms are followed across our facilities worldwide.

PIRAMAL DISCOVERY SOLUTIONS We, Piramal Discovery Solutions (formerly known as O2h) are an integral part of Piramal Pharma Solutions and deliver early stage drug discovery services to Pharma companies, Biotech companies and Academic institutions. Our 10,000 m² (100,000+ ft²) greenfield campus is located in a Special Economic Zone (SEZ), which is a government sponsored industrial park with specialized infrastructure to encourage export and industrialization. Our campus benefits from on-site customs clearance, central waste and power management and secure buildings with access control points. Our modern and advanced facility hosts 28 lab units (12 fume-hood reconfigurable modules), a write-up area and research campus that accommodates over 300 scientists. Our specialized areas are Medicinal and Synthetic Chemistry In vitro and in vivo Pharmacology Integrated Drug Discovery

MEDICINAL AND SYNTHETIC CHEMISTRY We are a reputed service provider of discovery chemistry. We have partnered with a range of well known pharmaceutical and biotechnology companies from Europe, USA and Japan. Our specialized team at PDS has a wide array of experience in preparing small molecule NCEs with the requisite high quality specifications. Our medicinal chemistry expertise includes hit expansion, hit to lead optimisation, lead generation and lead optimisation. All of these can be accessed as stand-alone offerings or as a part of an integrated drug discovery project. Our demonstrated expertise lies in the following chemistries Complex / multi-stage synthesis Heterocyclic Chiral Carbohydrate Peptide Aliphatic Nucleoside Natural product Our techniques include Microwave chemistry High pressure chemistry Cryogenic chemistry Parallel synthesis

Our specificities include Cambridge (UK) project office providing logistical, communications and objective project management support We have perfected clear templates which enable the systematic day-to-day reporting and measurement of scientific progress in the most effective manner Performance and productivity metrics are represented in a graphical form and shared internally as well as with the client Communications with clients range from direct communication to secure space on our intranet site for depositing documents and data arising during the projects Our dedicated team of personnel includes purchasing officers, store/stock managers as well as in-house customs liaising officer for efficient sourcing of starting materials Our IP (Intellectual Property) security model is designed to protect the IP of the clients during the project lifecycle and beyond Our scientists at are supported by a 360 º support system which aims at maximising their time to focus on their projects We value integrity in communication and action; social responsibility with respect to waste management and making a contribution to the community Our capabilities include Synthesis of small molecules on mg to kg scale (non-gmp) with the required high quality specifications, using diverse synthetic methodologies Modular custom-built lab units accommodating 12 FTE chemists each Lab units can be tailored to customer requirement, with key-card access and IP / IP security Supported with latest equipment - NMR, LC-MS / MS, microwave, combiflashes and access to literature (journals, patents etc.) Typical projects undertaken by us include: design and synthesis of discrete or series of compounds, as well as synthesis of focused libraries for SAR / SPR optimization

IN VITRO & IN VIVO PHARMACOLOGY Our biology facilities have been developed to provide faster decision-making points for our chemistry clients. Since 2008, we have doubled both our capacity as well as capability to include a range of pharmacology services to evaluate activity and/or potential liability of compounds. Currently, we are executing biology studies for several of our clients whose medicinal chemistry work is also being carried out by us; thus reducing the iterative cycle time of drug discovery and helping clients progress their compounds faster through the discovery stage. The biology work is available on a stand-alone basis as well as part of an integrated drug discovery project. I. In vitro assays ADME: solubility, permeability, CYP inhibition / induction, plasma stability (across different species), microsomal / S9 stability (across different species), plasma protein binding Target-based: enzymatic / kinase assays, binding assays, GPCR assays Cell-based: ELISA, proliferation, apoptosis, phosphorylation status, insulin sensitizer assays, cytokine production assays using hpbmcs, signal transduction assays II. In vivo assays Collagen-induced arthritis Adjuvant-induced arthritis DSS-induced colitis TNBS-induced colitis PMA-induced psoriasis / atopic dermatitis IMQ-induced psoriasis / atopic dermatitis Diet-induced obesity model Fat tolerance test Glucose tolerance test STZ-induced diabetes Cytokine release Single / repeat dose acute toxicity Oral bioavailability / tissue distribution studies Our capabilities Purpose-built labs include industry standard formats of fluorescence, luminescence and absorbance to help develop and optimize biochemical and / or cellular assays in a range of therapeutic areas In-depth expertise in pathophysiologically relevant experimental models for multiple therapeutic indications For in vivo studies, the macroscopic observations can be corroborated with a range of different techniques including but not limited to histopathological analysis, estimation of haematological and / or biochemical parameters etc Currently, the in vivo studies are performed only with rodents (e.g. mice, rats) Customization of assays based on client s requirement(s)

INTEGRATED DRUG DISCOVERY Our highly skilled team of scientists deliver services in Integrated Drug Discovery (IDD) projects incorporating medicinal chemistry (lead generation, hit-to-lead and lead optimisation), and in vitro and in vivo pharmacology. We offer expertise in multiple therapeutic indications. We consider the ultimate metric to measure the success of an IDD project is the capacity to create intellectual property and value to our customers. Our goal of IDD is to afford our clients access to specialized skills without incurring their own fixed costs and operating in a dynamic, flexible manner that suits the competitive commercial environment of drug discovery. Successful IDD projects rely on efficient integration of various disciplines Medicinal chemistry In vitro & in vivo discovery biology / pharmacology ADMET Computer-Aided Drug Discovery Operational excellence and expertise Each of the varied modules of the drug discovery process is available as a unique point of entry individually as a subset of services or as the traditional drug discovery pathway from hit identification through to lead generation and beyond. Our expertise includes medicinal chemistry: hit expansion, hit to lead, lead generation/ optimization, computational chemistry, in vitro enzymatic and cell-based screening, DMPK and in vivo models in multiple therapeutic areas.

Our Core Values Our Intellectual Property Policy The cornerstone of our philosophy on intellectual property rights (IPR) is built on upholding the IP generated by the company and all its associates. In order to achieve this objective, we have set up various systems which ensure that we: Respect the IPR of all its clients, partners and competitors Do not infringe any process or product knowingly and / or unknowingly Protect and enforce the IPR of the Company, our clients and partners Introduce measures to reduce IPR infringement related risks Promote a culture of IPR compliance within the organization Conduct periodic Intellectual Property Audits for effective IPR management and monitoring Respect for IP We value the relationships we have built with our customers. We believe that Customer Centricity is the driver behind all our actions. Our performance is measured on the value delivered to our customers. We partner with our customers in developing and delivering solutions. Customer Centricity Client Quality All our manufacturing sites have been approved by leading global regulatory agencies. All major sites have been approved by the US-FDA without any 483s Our aspiration is to be the best in class in global standards. Our process has evolved through the stages of: Create robust quality base Strengthen and implement system Quality culture across the organization Execute best in class standards Environment We function as an environmental-friendly organization and our practices have enabled us to Pursue continuous improvement: Periodic audits and gap analysis are conducted by Corporate EHS and cross functional teams Implementing EHS best practices through: ISO: 14001 and OHSAS: 18001 Aim towards the goal of Sustainable Development by targeting the triple bottom line growth in the fields of Economics, Environment and Society Ensuring continuity of the business processes through Business Continuity Plans Execute Process safety by implementing safety systems at all sites Enhance awareness, knowledge and skills of employees towards a safe, clean, greener and healthier work place Win Awards and Recognition Safety Award from National Safety Council of India, 2004 and 2005 Runners-up at the NE Business Awards Corporate Responsibility & Environment, 2009 CII-National Award for Energy Efficient Operations, 2009 Winner of State s Environment Award, 2010 Golden Peacock Award for Occupational Health & Safety, 2012 Frost and Sullivan s Green Manufacturing Excellence award, 2012

Products & Services across the drug lifecycle Drug Lifecycle Discovery Pre-clinical Phase I Phase II Phase III Launch On-patent Off-patent Core Services Phase API Late Phase Late Phase Formulations Late Phase Formulations Off patent API Off patent API On-patent Off-patent On-patent Launch Launch Off-patent Phase III DRUG LIFECYCLE DRUG LIFECYCLE Drug Discovery Services Drug Discovery Services Discovery Discovery Pre-clinical Phase II Pre-clinical Phase I Phase I Early Early Phase Phase API API Early Early Phase Phase Formulations Formulations For further details on Piramal Discovery Solutions contact us at Frédéric Somny, Ph.D. Head-Business Development Email: frederic.somny@piramal.com Mobile: +33 683 359 372 www.piramaldiscoverysolutions.com Our other services API Services Phase III Phase II API Generics Formulation Services Antibody Drug Conjugation Antibody Drug Conjugates Off-patent Discovery Antibody Drug Conjugates Special Services On-patent Off-patent On-patent Launch Launch Phase III Phase III DRUG LIFECYCLE DRUG LIFECYCLE Discovery Pre-clinical Phase II Phase II Pre-clinical Phase I Phase I Clinical Trial Supplies Clinical Trial Supplies Packaging Packaging Biocatalysis Biocatalysis

Piramal Enterprises Limited 247 Business Park, A - Wing, 6th floor, LBS Marg, Vikhroli (W), Mumbai 400 083. India. Phone: +91 22 3095 6666 Fax: +91 22 3095 6665 Email: strategicmarketing.cell@piramal.com PPS/PDS/OCT2012